Oncolys Biopharma 4588.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4588.T. It has been listed since 6 December 2013. In the fiscal year to 31 December 2025, it reported revenue of ¥28.5m and a net loss of ¥2.06bn. At that date it held total assets of ¥4.56bn and shareholders' equity of ¥4.00bn.

Oncolys BioPharma, Inc. engages in the research and development of cancer treatment therapy and diagnostics which include early detection, loco-regional therapy, prognostic test, and systemic treatments. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2013-12-06. The firm operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The firm's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Yasuo UrataPresident, Chief Executive Officer, Chairman & CEO of Subsidiary, Representative Director, since 2004
• Mr. Tetsuji YoneoDirector of Accounting & Finance, Executive Officer
• Ms. Megumi TaguchiDirector of HR Strategy, Executive Officer
• Mr. Koichi FukinoExecutive Officer, Director of Drug Discovery Planning
• Mr. Kohei HataExecutive Officer, Director of Business Planning
• Mr. Shuichi IsoyamaExecutive Officer, Director of Development
• Mr. Toshiaki KubotaExecutive Officer, Chief Director of Production Adjustment
• Mr. Keiji YoshimuraDirector
• Mr. Yasunari KashiharaDirector, since 2008
• Ms. Naoko IinoIndependent Director
• Mr. Toru SaitoIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.